Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer.
Aged
Antigens, CD
CD4-Positive T-Lymphocytes
CD8-Positive T-Lymphocytes
/ immunology
Female
Granzymes
/ metabolism
Humans
Immune Checkpoint Inhibitors
/ therapeutic use
Immunity, Cellular
Integrin alpha Chains
Interferon-gamma
/ metabolism
Kaplan-Meier Estimate
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Prognosis
Programmed Cell Death 1 Receptor
/ metabolism
ROC Curve
Stomach Neoplasms
/ immunology
Tertiary Lymphoid Structures
/ immunology
Tumor Microenvironment
/ immunology
CD103
antitumor immunity
gastric cancer
tertiary lymphoid structure
tissue-resident memory T cell
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
revised:
18
02
2021
received:
12
11
2020
accepted:
14
03
2021
pubmed:
19
3
2021
medline:
11
5
2021
entrez:
18
3
2021
Statut:
ppublish
Résumé
Several studies have reported that tissue-resident memory T cells (TRM cells) or tertiary lymphoid structures (TLSs) are associated with a good prognosis. The aim of this study was to clarify the association of TRM cells and TLSs in the tumor immune microenvironment in gastric cancer (GC). We performed immunohistochemical and immunofluorescence staining to detect the presence of CD103
Identifiants
pubmed: 33735485
doi: 10.1111/cas.14888
pmc: PMC8088970
doi:
Substances chimiques
Antigens, CD
0
Immune Checkpoint Inhibitors
0
Integrin alpha Chains
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
alpha E integrins
0
Interferon-gamma
82115-62-6
GZMB protein, human
EC 3.4.21.-
Granzymes
EC 3.4.21.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1746-1757Informations de copyright
© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Eur J Immunol. 2001 May;31(5):1544-9
pubmed: 11465112
Am J Pathol. 1991 Jul;139(1):17-23
pubmed: 1713020
Cancer Sci. 2021 May;112(5):1746-1757
pubmed: 33735485
Cancer Immunol Res. 2019 May;7(5):784-796
pubmed: 30872264
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Immunother Cancer. 2018 Sep 4;6(1):87
pubmed: 30180905
Cancer Immunol Immunother. 2020 Aug;69(8):1493-1504
pubmed: 32285170
Int J Oncol. 2020 Jul;57(1):171-182
pubmed: 32319601
J Clin Invest. 2015 Sep;125(9):3335-7
pubmed: 26325031
J Surg Res. 2014 Jan;186(1):192-200
pubmed: 24120241
Nat Immunol. 2017 Aug;18(8):940-950
pubmed: 28628092
Nat Immunol. 2018 Jun;19(6):538-546
pubmed: 29777219
Front Immunol. 2015 Feb 23;6:67
pubmed: 25755654
Cancers (Basel). 2014 Apr 23;6(2):969-97
pubmed: 24762633
Clin Exp Immunol. 2018 Oct;194(1):39-53
pubmed: 30009527
Oncotarget. 2017 May 3;8(37):62312-62329
pubmed: 28977947
Cancer Immunol Immunother. 2013 Mar;62(3):405-10
pubmed: 23423351
J Surg Res. 2017 Jul;215:74-82
pubmed: 28688665
J Cancer. 2019 Aug 28;10(21):5234-5243
pubmed: 31602274
Front Immunol. 2013 Dec 19;4:455
pubmed: 24391639
Nat Rev Immunol. 2016 Feb;16(2):79-89
pubmed: 26688350
J Immunol. 2015 Apr 1;194(7):3475-86
pubmed: 25725111
Clin Cancer Res. 2016 Jun 15;22(12):3005-15
pubmed: 26763251
Br J Cancer. 2020 May;122(10):1525-1534
pubmed: 32205862
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
Nat Med. 2018 Jul;24(7):994-1004
pubmed: 29892065
JCI Insight. 2017 Jun 2;2(11):
pubmed: 28570278
Cancer Immunol Res. 2015 Aug;3(8):926-35
pubmed: 25957117
Immunol Rev. 2016 May;271(1):260-75
pubmed: 27088920
Medicine (Baltimore). 2018 Aug;97(32):e11769
pubmed: 30095632
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Oncoimmunology. 2020 Nov 22;9(1):1844402
pubmed: 33312758
Clin Cancer Res. 2014 Jan 15;20(2):434-44
pubmed: 24190978
Immunity. 2018 Feb 20;48(2):202-213
pubmed: 29466753
Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44
pubmed: 24484236
BMC Cancer. 2015 Mar 06;15:101
pubmed: 25884667
Clin Cancer Res. 2018 Jul 1;24(13):3036-3045
pubmed: 29599411